| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/25/2001 | WO2001036608A1 Reversibly inactivated acidified plasmin |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036602A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| 05/25/2001 | WO2001036479A1 G-protein coupled receptor |
| 05/25/2001 | WO2001036462A2 Protein c derivatives |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036450A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | WO2001036440A1 23 human secreted proteins |
| 05/25/2001 | WO2001036438A1 Novel ribose compounds |
| 05/25/2001 | WO2001036437A1 β-D-5-THIOXYLOSE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | WO2001036421A1 Novel [1,2,3]-triazolo[4,5-d]pyrimidine compounds |
| 05/25/2001 | WO2001036420A1 Tricyclic azaindolizine derivatives having an spla2- inhibiting effect |
| 05/25/2001 | WO2001036416A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | WO2001036403A1 Urea derivatives as anti-inflammatory agents |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036376A1 Novel phenylalanine derivatives |
| 05/25/2001 | WO2001036374A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 05/25/2001 | WO2001036365A2 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 05/25/2001 | WO2001036360A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 05/25/2001 | WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035967A1 Heparanase inhibitors for the treatment of heart failure |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035958A1 Carvedilol methanesulfonate |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | WO2001013905A3 Methods for the treatment of mental and vascular disorders |
| 05/25/2001 | WO2001007023A3 Azetidine compounds in cns and eye diseases |
| 05/25/2001 | WO2000078330A3 Adenosine diphosphatase and activators thereof and their medical uses |
| 05/25/2001 | WO2000064426A3 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 05/25/2001 | WO2000042998A9 Multiparticulate bisoprolol formulation |
| 05/25/2001 | WO2000032555A8 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 05/25/2001 | WO1999033841B1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 05/25/2001 | CA2392090A1 G-protein coupled receptor |
| 05/25/2001 | CA2392085A1 Carvedilol methanesulfonate |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391969A1 S-allylmercaptoglutathione and uses thereof |
| 05/25/2001 | CA2391913A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | CA2391651A1 Protein c derivatives |
| 05/25/2001 | CA2391531A1 Placental human neurokinin b precursor |
| 05/25/2001 | CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties |
| 05/25/2001 | CA2391291A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | CA2391100A1 .beta.-d-5-thioxylose derivatives, preparation method and therapeutic use |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2390031A1 Double-stranded rna receptor (dsrna-r) and methods relating thereto |
| 05/25/2001 | CA2389862A1 Human monoclonal antibody against tgf-.beta.ii receptor and medicinal use thereof |
| 05/25/2001 | CA2389487A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | CA2388922A1 23 human secreted proteins |
| 05/24/2001 | US20010001799 Anticoagulant |
| 05/23/2001 | EP1101769A2 Nitrogen Containing Erythromycin Derivatives |
| 05/23/2001 | EP1101763A2 Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| 05/23/2001 | EP1101757A1 Heterocyclic compounds as tachykinin receptor antagonists |
| 05/23/2001 | EP1101756A1 Aminopyrrolidine derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| 05/23/2001 | EP1100964A1 Gene sequence variances with utility in determining the treatment of disease |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100910A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100908A2 Human receptor-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100896A1 Dna encoding snorf33 receptor |
| 05/23/2001 | EP1100895A2 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100870A1 Improvement of cardiac function by mesenchymal stem cell transplantation |
| 05/23/2001 | EP1100869A1 98 human secreted proteins |
| 05/23/2001 | EP1100826A1 Isoforms of human calcium sensing receptor |
| 05/23/2001 | EP1100822A1 Secreted cysteine rich protein-6 (scrp-6) |
| 05/23/2001 | EP1100814A2 Inhibitors of urokinase and blood vessel formation |
| 05/23/2001 | EP1100813A1 HUMAN BOMBESIN RECEPTOR SUBTYPE-3sb |
| 05/23/2001 | EP1100808A1 Prostate derived ets factor |
| 05/23/2001 | EP1100801A2 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein |
| 05/23/2001 | EP1100794A1 COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF |
| 05/23/2001 | EP1100792A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 05/23/2001 | EP1100790A1 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them |
| 05/23/2001 | EP1100780A1 Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz f]indoles, a method for the production thereof, and their use as medicaments |
| 05/23/2001 | EP1100775A2 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same |
| 05/23/2001 | EP1100767A1 Novel phenylethylamine derivatives, a method for the production thereof and their use as medicaments |
| 05/23/2001 | EP1100547A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 05/23/2001 | EP1100541A1 Hydrogel for the therapeutic treatment of aneurysms |
| 05/23/2001 | EP1100538A2 Kvlqt1 - a long qt syndrome |
| 05/23/2001 | EP1100535A1 Targeting pharmaceutical agents to injured tissues |
| 05/23/2001 | EP1100532A2 Methods of using lanreotide, a somatostatin analogue |
| 05/23/2001 | EP1100525A2 Modulation of apoptosis |
| 05/23/2001 | EP1100521A1 C7f2-a novel potassium channel beta-subunit |
| 05/23/2001 | EP1100519A1 Multibinding agents that modulate nmda receptors |
| 05/23/2001 | EP1100495A1 Propenamides as ccr5 modulators |
| 05/23/2001 | EP1100493A1 INDOLE sPLA 2? INHIBITORS |
| 05/23/2001 | EP1100492A1 INDOLE sPLA 2? INHIBITORS |
| 05/23/2001 | EP1100486A1 Macrophage scavenger receptor antagonists |
| 05/23/2001 | EP1100484A1 Macrophage scavenger receptor antagonists |
| 05/23/2001 | EP1100476A1 Formulations for the transdermal administration of fenoldopam |
| 05/23/2001 | EP1100469A1 Rapidly disintegrable solid preparation |
| 05/23/2001 | EP1100462A2 Methods of ophthalmic administration |
| 05/23/2001 | EP0900218A4 Heterocyclic compounds |
| 05/23/2001 | EP0812835B1 Optically active thiazolidinone derivatives |